Spinal cord injuries create a glial scar — a dense mass of scar tissue that forms a physical and chemical barrier to nerve regeneration. The scar is the body's response to injury: stabilize the damage site, prevent further degeneration, wall off the wound. It works as acute defense. It fails as long-term strategy, because the wall that prevents spread also prevents repair. Neurons cannot extend through scar tissue. The injury is contained and permanent.
Researchers at Northwestern, led by Samuel Stupp, developed supramolecular therapeutic peptides — assemblies of over 100,000 molecules that form nanofibers and activate cell receptors using the body's own regenerative signals. They call the therapy “dancing molecules” because the peptides' rapid molecular motion is critical to their function. The motion allows the molecules to find and engage cell receptors more effectively than static structures. In a 2021 animal study, the therapy reversed paralysis in mice.
Published in Nature Biomedical Engineering, the new study tests the therapy on human spinal cord organoids — miniature organs grown from stem cells that replicate the key features of spinal cord tissue. When injured, the organoids develop glial scarring, cell death, and inflammation that mirrors actual spinal cord injury. When treated with the dancing molecules, the organoids showed significant neurite outgrowth — long neural extensions reconnecting across the injury site — and the glial scar diminished.
The structural insight is about the scar as decision point. The body's response to spinal cord injury is not wrong. Scarring prevents catastrophic spread of damage. But the same response that saves the acute phase condemns the chronic phase. The scar is simultaneously protective and obstructive — the right response at the wrong timescale. The dancing molecules don't prevent scarring. They resolve it after it has done its protective work, converting the injury site from a wall back into a bridge.
The therapy has received FDA Orphan Drug Designation. The organoid model matters because human spinal cord tissue cannot be experimentally injured — the organoid provides the testing ground that ethics forbids. The model organism for the human spinal cord is not a mouse or a rat. It is a miniature human spinal cord grown in a dish.